Literature DB >> 9654611

Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia.

S W Walsh1.   

Abstract

This review addresses the general hypothesis that the pathogenesis of preeclampsia is related to an imbalance of increased oxidative stress and lipid peroxidation coupled to a deficiency of antioxidant protection. Evidence will be presented that this imbalance is present in both the maternal compartment and the placental compartment and that interactions between these two compartments result in the clinical manifestations of this disorder. We suggest the following as a scenario for the development of preeclampsia: Oxidative stress in the maternal compartment affects the placenta in such a way as to bring about a decrease in placental antioxidant enzyme protection. The oxidative stress in the maternal compartment may be preexisting (e.g., obesity, diabetes, hyperlipidemia) or may be caused by placental secretion of lipid peroxides. Decreased placental antioxidant enzyme protection leads to a cascade of events in the placenta of uncontrolled lipid peroxidation with increased thromboxane production and increased tumor necrosis factor (TNF-alpha) production. Increased placental secretion of lipid peroxides and/or TNF-alpha results in activation of leukocytes as they circulate through the intervillous space. The activated leukocytes serve as circulating mediators that link the increased oxidative stress of the placenta with a widespread increase in oxidative stress and endothelial dysfunction in the mother. In the third trimester, when the placenta is growing rapidly, the mother's antioxidant capacity is no longer able to compensate, and the clinical symptoms of preeclampsia appear.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9654611     DOI: 10.1055/s-2007-1016256

Source DB:  PubMed          Journal:  Semin Reprod Endocrinol        ISSN: 0734-8630


  54 in total

1.  Neutrophil release of myeloperoxidase in systemic vasculature of obese women may put them at risk for preeclampsia.

Authors:  Juhi Shukla; Scott W Walsh
Journal:  Reprod Sci       Date:  2014-11-12       Impact factor: 3.060

2.  Recent insights into the pathophysiology of preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Expert Rev Obstet Gynecol       Date:  2010-09-01

3.  Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2012-08

4.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia.

Authors:  B Lamarca
Journal:  Minerva Ginecol       Date:  2010-04

5.  What causes endothelial cell activation in preeclamptic women?

Authors:  Scott W Walsh
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

Review 6.  Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Jeffery Gilbert; Joey P Granger
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

7.  DNA methylation is altered in maternal blood vessels of women with preeclampsia.

Authors:  Ahmad A Mousa; Kellie J Archer; Renato Cappello; Guadalupe Estrada-Gutierrez; Christine R Isaacs; Jerome F Strauss; Scott W Walsh
Journal:  Reprod Sci       Date:  2012-08-17       Impact factor: 3.060

8.  Mechanisms of enhanced vascular reactivity in preeclampsia.

Authors:  Nikita Mishra; William H Nugent; Sunila Mahavadi; Scott W Walsh
Journal:  Hypertension       Date:  2011-09-26       Impact factor: 10.190

9.  MiR-101 regulates apoptosis of trophoblast HTR-8/SVneo cells by targeting endoplasmic reticulum (ER) protein 44 during preeclampsia.

Authors:  Y Zou; Z Jiang; X Yu; Y Zhang; M Sun; W Wang; Z Ge; W De; L Sun
Journal:  J Hum Hypertens       Date:  2014-05-08       Impact factor: 3.012

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.